Company Name: |
Finetech Industry Limited |
Tel: |
+86-27-87465837 +8618971612321 |
Email: |
info@finetechnology-ind.com |
Products Intro: |
Product Name:3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,6-dioxopyrimidine-4-carboxylic acid CAS:314-50-1 Purity:98% Package:1g,10g,25g,100g,500g,1kg
|
|
|
|
|
OROTIDINE manufacturers
- Orotidine
-
- $1.00 / 1KG
-
2024-05-21
- CAS:314-50-1
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20t
|
| OROTIDINE Basic information |
Product Name: | OROTIDINE | Synonyms: | OROTIDINE;URIDINE-6-CARBOXYLIC ACID;URIDIN-6-CARBOXYLIC ACID;Orotidine (Uridine-6-carboxylic acid);1,2,3,6-Tetrahydro-2,6-dioxo-3-β-D-ribofuranosyl-4-pyrimidinecarboxylic acid;6-Carboxyuridine;3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]-2,6-diketo-pyrimidine-4-carboxylic acid;Orotidine ,98% | CAS: | 314-50-1 | MF: | C10H12N2O8 | MW: | 288.21 | EINECS: | | Product Categories: | | Mol File: | 314-50-1.mol |  |
| OROTIDINE Chemical Properties |
Melting point | >400 °C | density | 1.847±0.06 g/cm3(Predicted) | storage temp. | −20°C | solubility | DMSO (Slightly), Methanol (Slightly), Water (Slightly) | form | Solid | pka | 2.62±0.20(Predicted) | color | White to Off-White |
WGK Germany | 3 | HS Code | 29349990 |
| OROTIDINE Usage And Synthesis |
Uses | Orotidine is a metabolite of Orotic Acid (O691500); a compound used in the preparation of therapeutic agents for chronic obstructive pulmonary disease (COPD) treatment. | Definition | ChEBI: A nucleoside formed by attaching orotic acid to a ribose ring via a beta1N(1)-glycosidic bond. | Enzyme inhibitor | This water-soluble ribonucleoside (FWfree-acid = 288.21 g/mol; CAS 314-50- 1; lmax of 267 nm in 0.1 N HCl (e = 9570 cm–1M–1; another report lists 9800) and 265 nm in 0.1 N methanolic NaOH (e = 8960 cm–1M–1; another report lists 7800)), first observed in Neurospora crassa, is also foound in the urine of cancer patients treated with 6-azauridine, Orotidine is most likely formed from OMP, its 5’-monophosphate ester and the direct precursor of UMP. Orotidine is readily hydrolyzed in dilute mineral acids. Target(s): orotate phosphoribosyltransferase; orotidine-5’-phosphate decarboxylase. |
| OROTIDINE Preparation Products And Raw materials |
|